Literature DB >> 15991006

Concomitant deregulation of HIF1alpha and cell cycle proteins in VHL-mutated renal cell carcinomas.

Derek John Atkins1, Christian Gingert, Christina Justenhoven, Gerd Emil Schmahl, Marcellus Stephanus Bonato, Hiltrud Brauch, Stephan Störkel.   

Abstract

Renal cell carcinomas (RCCs) of the clear cell type are associated with alteration of the von Hippel-Lindau (VHL) tumour suppressor gene as well as subsequent stabilization and over-expression of hypoxia inducible factor (HIF), which causes up-regulation of cyclin D1. On the basis of their ability to interact with cyclin D1 we investigated a number of cell cycle proteins to shed further light on the downstream effects of HIF dysregulation. Expression of HIF1alpha, cyclin D1, cyclin-dependent kinase 4 and cyclin-dependent kinase inhibitors p16, p21 and p27 was studied by immunohistochemistry. Since NFkappaB1/RelA have been shown to bind to the cyclin D1 promoter, mRNA expression of these transcription factors was further analysed by quantitative PCR. In RCCs harbouring VHL mutations/hypermethylation, over-expression of HIF1alpha was parallelled by up-regulation of cyclin D1 and CDK4 and down-regulation of p21 and p27. Moreover, p27 expression was inversely correlated with tumour cell differentiation. Comparison of non-tumorous autologous kidney tissues revealed a significant down-regulation of NFkappaB1 mRNA expression in patients harbouring RCC with VHL mutations/hypermethylation. Our data support the notion of a link between VHL deficiency/HIF dysfunction and disturbances of cell cycle control in the tumorigenesis of VHL-negative RCC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15991006     DOI: 10.1007/s00428-005-1262-y

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  32 in total

1.  Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.

Authors:  M S Wiesener; P M Münchenhagen; I Berger; N V Morgan; J Roigas; A Schwiertz; J S Jürgensen; G Gruber; P H Maxwell; S A Löning; U Frei; E R Maher; H J Gröne; K U Eckardt
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

Review 2.  Hypoxia-inducible factor 1 and the molecular physiology of oxygen homeostasis.

Authors:  G L Semenza
Journal:  J Lab Clin Med       Date:  1998-03

3.  VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells.

Authors:  Ranjit S Bindra; James R Vasselli; Robert Stearman; W Marston Linehan; Richard D Klausner
Journal:  Cancer Res       Date:  2002-06-01       Impact factor: 12.701

4.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

5.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Authors:  P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

6.  The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal.

Authors:  A Pause; S Lee; K M Lonergan; R D Klausner
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

7.  Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan.

Authors:  B Zbar; T Kishida; F Chen; L Schmidt; E R Maher; F M Richards; P A Crossey; A R Webster; N A Affara; M A Ferguson-Smith; H Brauch; D Glavac; H P Neumann; S Tisherman; J J Mulvihill; D J Gross; T Shuin; J Whaley; B Seizinger; N Kley; S Olschwang; C Boisson; S Richard; C H Lips; M Lerman
Journal:  Hum Mutat       Date:  1996       Impact factor: 4.878

8.  Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics.

Authors:  W Thoenes; S Störkel; H J Rumpelt
Journal:  Pathol Res Pract       Date:  1986-05       Impact factor: 3.250

9.  Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.

Authors:  Malgorzata Zatyka; Nancy Fernandes da Silva; Steven C Clifford; Mark R Morris; Michael S Wiesener; Kai-Uwe Eckardt; Richard S Houlston; Frances M Richards; Farida Latif; Eamonn R Maher
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

10.  Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.

Authors:  Masaya Baba; Syuiohi Hirai; Hisafumi Yamada-Okabe; Kenji Hamada; Hisahiro Tabuchi; Kazuki Kobayashi; Keiichi Kondo; Minoru Yoshida; Akio Yamashita; Takeshi Kishida; Noboru Nakaigawa; Youji Nagashima; Yoshinobu Kubota; Masahiro Yao; Shigeo Ohno
Journal:  Oncogene       Date:  2003-05-08       Impact factor: 9.867

View more
  10 in total

Review 1.  Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.

Authors:  Johannes Schödel; Steffen Grampp; Eamonn R Maher; Holger Moch; Peter J Ratcliffe; Paul Russo; David R Mole
Journal:  Eur Urol       Date:  2015-08-19       Impact factor: 20.096

2.  Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma.

Authors:  Alison C Young; Rachel A Craven; Dena Cohen; Claire Taylor; Christopher Booth; Patricia Harnden; David A Cairns; Dewi Astuti; Walter Gregory; Eamonn R Maher; Margaret A Knowles; Adrian Joyce; Peter J Selby; Rosamonde E Banks
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

Review 3.  Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma.

Authors:  Rebecca A Sager; Sarah J Backe; Elham Ahanin; Garrett Smith; Imad Nsouli; Mark R Woodford; Gennady Bratslavsky; Dimitra Bourboulia; Mehdi Mollapour
Journal:  Nat Rev Urol       Date:  2022-03-09       Impact factor: 16.430

4.  Hypoxia-inducible factor (HIF)-independent expression mechanism and novel function of HIF prolyl hydroxylase-3 in renal cell carcinoma.

Authors:  Toshiaki Tanaka; Toshihiko Torigoe; Yoshihiko Hirohashi; Eiji Sato; Ichiya Honma; Hiroshi Kitamura; Naoya Masumori; Taiji Tsukamoto; Noriyuki Sato
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-30       Impact factor: 4.553

5.  Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.

Authors:  Lee E Moore; Michael L Nickerson; Paul Brennan; Jorge R Toro; Erich Jaeger; Jessica Rinsky; Summer S Han; David Zaridze; Vsevolod Matveev; Vladimir Janout; Hellena Kollarova; Vladimir Bencko; Marie Navratilova; Neonilia Szeszenia-Dabrowska; Dana Mates; Laura S Schmidt; Petra Lenz; Sara Karami; W Marston Linehan; Maria Merino; Stephen Chanock; Paolo Boffetta; Wong-Ho Chow; Frederic M Waldman; Nathaniel Rothman
Journal:  PLoS Genet       Date:  2011-10-13       Impact factor: 5.917

6.  Novel interactions of the von Hippel-Lindau (pVHL) tumor suppressor with the CDKN1 family of cell cycle inhibitors.

Authors:  Giovanni Minervini; Raffaele Lopreiato; Raissa Bortolotto; Antonella Falconieri; Geppo Sartori; Silvio C E Tosatto
Journal:  Sci Rep       Date:  2017-04-20       Impact factor: 4.379

7.  Seven Novel Genes Related to Cell Proliferation and Migration of VHL-Mutated Pheochromocytoma.

Authors:  Shuai Gao; Longfei Liu; Zhuolin Li; Yingxian Pang; Jiaqi Shi; Feizhou Zhu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-22       Impact factor: 5.555

8.  Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma.

Authors:  Luke J Nelson; Kyleen E Castro; Binzhi Xu; Junyi Li; Nguyen B Dinh; Jordan M Thompson; Jordan Woytash; Kevin R Kipp; Olga V Razorenova
Journal:  Cell Cycle       Date:  2022-03-04       Impact factor: 5.173

9.  Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells.

Authors:  Eva Juengel; Johanna Engler; Iyad Natsheh; Jon Jones; Ausra Mickuckyte; Lukasz Hudak; Dietger Jonas; Roman A Blaheta
Journal:  BMC Cancer       Date:  2009-05-27       Impact factor: 4.430

10.  Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo.

Authors:  Eva Juengel; Jasmina Makarević; Igor Tsaur; Georg Bartsch; Karen Nelson; Axel Haferkamp; Roman A Blaheta
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.